Navigation Links
Antibody-guided drug works against acute lymphoblastic leukemia

HOUSTON An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

Patients enrolled in the trial led by investigators at The University of Texas MD Anderson Cancer Center had ALL that resisted other therapies or recurred after treatment.

"A response rate of more than 50 percent in this patient population probably makes inotuzumab ozogamicin the most active single-agent therapy ever for ALL," said Hagop Kantarjian, M.D., professor and chair of MD Anderson's Department of Leukemia and study senior investigator.

ALL is an aggressive form of leukemia in which immature white blood cells, called lymphoblasts, grow rapidly, crowding out normal blood cells.

The drug, also known as CMC-544, links an antibody that targets CD22, a protein found on the surface of more than 90 percent of ALL cells, and the cytotoxic agent calicheamicin. Once the drug connects to CD22, the ALL cell draws it inside and dies.

Response rate for other second options is 20-30 percent

Kantarjian said second-line chemotherapy combinations used for ALL typically have a complete response rate of 20-30 percent. The monoclonal antibody-based drug developed by Pfizer, Inc., also is the first of its type for ALL.

The drug is safe, said Elias Jabbour, M.D., assistant professor in MD Anderson's Department of Leukemia, who will present the study results at ASCO on Monday, June 6. Almost all side-effects were of low grade (1-2) and manageable. Drug-induced fever was the most common side effect, reaching higher grades in nine of 48 patients.

Out of 46 patients evaluable for response, nine had a complete response, 14 had complete response without full recovery of platelets, and 5 had less than 5 percent blasts in their bone marrow without blood count recovery.

Sixteen responders subsequently received a donor blood stem cell transplant, Jabbour noted.

Drug combinations

Combining inotuzumab with other chemotherapy might further improve ALL treatment, Jabbour said. MD Anderson has a phase II clinical trial under way following inotuzumab treatment with another monoclonal antibody drug, rituximab, currently used in some types of non-Hodgkin's lymphoma.

Rituximab targets the CD20 surface protein, which occurs in 50 percent of ALL cells.

In addition to combinations, the authors suggest that a shift from dosing every three weeks to weekly should be explored.

Frontline therapy for ALL is a combination chemotherapy regimen known as HyperCVAD.

The National Cancer Institute estimates that 5,330 people received an ALL diagnosis in 2010 and 1,420 died of the disease.

ALL is the most common type of childhood cancer. Combined chemotherapy regimens have raised long-term survival from 5 percent of pediatric patients in the 1960s to 85 percent today.


Contact: Scott Merville
University of Texas M. D. Anderson Cancer Center

Related medicine news :

1. KPA and TK Carsites offer HR, OSHA and Internet Marketing Workshops at the NADA Convention and Expo 2010
2. For Some Breast Cancer Patients, Shorter Radiation Works Well
3. Swine Flu vaccination: voluntary system works
4. mHealth Alliance Works in Partnership with GSMA to Expand Discussion of Mobile Health at 2010 Mobile World Congress
5. BCS Global Launches PSVN (Public Switched Video Network), an Initiative to Provide a Framework for Inter-Connecting Business to Business Video Networks
6. Visionworks(R) Brings High Quality Eye Care & Eye Wear to Western PA
7. Dr. Alesia Wagner of U.S. HealthWorks Medical Group Re-elected to Board of Osteopathic Physicians and Surgeons of California
8. Abbott Research Group, Inc. Launches New Product - WaterWorks
9. Learn to Dance in a Day -- Beginner Workshop Launches Modern Jive in Toronto
10. Enterprise PDM Integration has Never Been Easier; Zero Wait-State Announces Leading SolidWorks Reseller GoEngineer as Master Distributor for DesignState
11. Easy to See and Use Senior Phone Works with AT&T and T-Mobile Cellular Providers
Post Your Comments:
Related Image:
Antibody-guided drug works against acute lymphoblastic leukemia
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology: